Definitive Healthcare Corp. Class A ((DH)) has held its Q4 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Definitive Healthcare Corp.’s latest earnings call painted a cautiously stabilizing picture for investors. Management highlighted resilient profitability, strong cash generation and tangible operational fixes, even as they acknowledged ongoing revenue pressure, softer net dollar retention and shorter contract durations that will weigh on growth in 2026.
Profitability Beats as Margins Expand
Definitive Healthcare delivered Q4 2025 adjusted EBITDA of about $18.1 million, translating to a 29% margin. That result came in roughly $1.1 million above the high end of guidance and marked margin expansion of around 120 basis points year over year, underscoring disciplined execution despite top-line pressure.
Cash Generation Supports Flexibility
Trailing 12‑month unlevered free cash flow reached roughly $54.9 million, with an adjusted EBITDA‑to‑unlevered FCF conversion of 78%. Management noted that conversion would have been about 87% excluding one‑time capital spending, leaving the company with ample financial flexibility to invest while defending profitability.
Professional Services and Digital Activations Accelerate
Professional services revenue jumped about 49% year over year in Q4 2025, fueled by increased digital activations and analytics work. Nearly 30 agency partners have now signed on for digital activation, and more than one‑third are already contributing bookings, creating a growing ancillary revenue stream.
Claims Data Fixes Restore an Edge
The company rolled out a fall expansion pack and added a new claims data source in the second half of 2025, lifting claims volumes above historical levels. It also layered in mobile phone data to bolster reference and affiliation datasets, moves that management believes will reinforce the platform’s long‑term data differentiation.
Deeper Integrations Shorten Time-to-Value
Definitive Healthcare deepened its integrations with Snowflake, Databricks and HubSpot while piloting Salesforce connectivity. These efforts helped cut integration time by roughly 25% during 2025 and added more than 60 integrated customers in Q4 alone, or 160 for the full year, which should support better retention and stickier customer relationships.
Retention Metrics Show Gradual Improvement
Gross dollar retention improved by about 2 percentage points year over year, with retention rates rising in each of the past three quarters. The company’s cohort analysis showed roughly 200 basis points of retention improvement in customers sold after the first quarter of 2024, suggesting newer business is behaving more favorably.
Cost Discipline Funds Targeted Investment
Despite revenue headwinds, the company maintained strong margins and held operating costs in check while ramping investment in innovation. Capitalized software spend rose to about $6 million, a $5 million increase from the prior year, as Definitive Healthcare restarted organic product development and pushed ahead on its AI‑enabled roadmap.
AI and Go-to-Market Tailwinds Emerging
Management plans to begin embedding generative AI into its flagship View platform as soon as next quarter. With more than 15 years of proprietary, longitudinal data and a base of roughly 2,300 customers—about half already integrating data into core systems—the company sees a meaningful AI‑driven and go‑to‑market opportunity over time.
Revenue Declines Highlight Top-Line Pressure
Q4 2025 revenue came in at $61.5 million, slipping 1% year over year, while full‑year 2025 revenue fell 4% to $241.5 million. Looking ahead, the 2026 revenue outlook of $220 million to $226 million implies a further 6% to 9% decline, signaling that growth challenges are not yet behind the company.
Net Dollar Retention Remains a Drag
Net dollar retention weakened in 2025 as upsell motions continued to face pressure, weighing on expansion revenue. Management expects only a modest improvement of a couple of points in NDR during 2026 and framed 2025 as the likely trough, but a robust rebound is not yet in sight.
Shorter Contracts Weigh on RPO
Total remaining performance obligations declined about 18% year over year, with current RPO at $165 million flat sequentially but down roughly 12% from last year. A shift toward one‑year deals reduced multi‑year commitments, with current RPO from longer‑term contracts dropping from about $100 million at the end of 2024 to roughly $85 million.
Negative Operating Leverage Looms
With a largely fixed cost base, management expects most of the projected 2026 revenue decline to flow through to earnings. The company is guiding to a full‑year adjusted EBITDA margin of 24% to 26% versus 29% in 2025, citing the lower revenue run‑rate and the absence of one‑time credits that boosted margins last year.
Cash Conversion Softer Versus Prior Year
Operating cash flow for 2025 was $53.8 million, down about 8% from the prior year as top‑line softness and higher investment took a toll. Adjusted EBITDA‑to‑unlevered FCF conversion slipped around 14 points to 78%, though management pointed to normalization adjustments and expects improvement in 2026 as capital spending eases.
Near-Term Revenue Headwinds Persist
Guidance for Q1 2026 calls for revenue between $54 million and $56 million, implying a 5% to 9% year‑over‑year decline. Given that the first quarter includes a heavy renewal cycle and only modest renewal rate improvement was seen in Q4, executives stressed that near‑term top‑line risk remains elevated.
Upsell Recovery Pushed to Later in 2026
Although claims data issues have been remediated and product improvements are rolling out, management cautioned that upsell and cross‑sell benefits will take time to materialize. They now expect expansion activity—key for a stronger NDR trend—to improve primarily in the back half of 2026 rather than immediately.
Guidance Signals Cautious 2026 With H2 Uptick
For Q1 2026, the company guided to adjusted operating income of $9.5 million to $10.5 million and adjusted EBITDA of $12 million to $13 million, or a 22% to 23% margin. Full‑year 2026 guidance calls for revenue of $220 million to $226 million, adjusted EBITDA of $53 million to $58 million at a 24% to 26% margin and slightly better cash conversion as lower CapEx offsets targeted growth investments.
Definitive Healthcare’s earnings call balanced solid execution on margins, cash flow and data‑driven product enhancements against a still‑challenged growth profile. For investors, the story now hinges on whether operational fixes, AI‑enabled offerings and deeper integrations can translate into a tangible recovery in renewals and upsells as 2026 progresses.